Atomoxetine ingestions in children: A report from poison centers

Annals of Pharmacotherapy

Volumn 39, Issue 6, 2005, Pages 1045-1048

  Spiller, Henry A ^a   Lintner, Chris P ^b   Winter, Mark L ^c  

^a KENTUCKY REGIONAL POISON CENTER   (United States)

^b Hennepin Regional Poison Center   (United States)

^c Southeast Texas Poison Center   (United States)

Author keywords

Adverse effect; Atomoxetine; Attention deficit hyperactivity disorder; Overdose

Indexed keywords

ACTIVATED CARBON; ATOMOXETINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG EXPOSURE; DRUG OVERDOSE; EMERGENCY WARD; FATALITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPERTENSION; INFANT; INGESTION; MALE; NAUSEA; POISON CENTER; POLYPHARMACY; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SINUS TACHYCARDIA; SUICIDE ATTEMPT; TACHYCARDIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; CHARCOAL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMERGENCY TREATMENT; FEMALE; HUMANS; HYPERTENSION; INFANT; MALE; POISON CONTROL CENTERS; PROPYLAMINES; SEIZURES; SELF ADMINISTRATION; SUICIDE, ATTEMPTED; TACHYCARDIA;

EID: 18844395143     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E646     Document Type: Article

References (14)

1. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83.
2. Kratochvil CJ, Bohac D, Harrington M, Baker N, May D, Burke WJ. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:167-70.
3. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose (letter). Am J Psychiatry 2004;161:757.
4. Barker MJ, Benitez JG, Ternulla S, Juhl GA. Acute oxcarbamazepine and atomoxetine overdose with quetiapine. Vet Hum Toxicol 2004;46:130-2.
5. Data on file. Indianapolis: Eli Lilly and Co., January 2005.
6. Watson WA, Litovitz TL, Klein-Schwartz W, Rodgers GC, Youniss J, Reid N, et al. 2003 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2004;22:335-404.
7. Zerbe RL, Rowe H, Enas GG, Wong D, Farid N, Lemberger L. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther 1985;232:139-43.
8. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-65.
9. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:251-65.
10. Spencer T, Biederman J, Wilens TE, Faraone SV. Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 1998;59(suppl 7):59-68.
11. Chouinard G, Annable L, Bradwejn J, Labonte A, Jones B, Mercier P, et al. An early Phase II clinical trial with follow-up of atomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol Bull 1985;21:73-6.
12. Wernicke JF, Faries D, Girod D, Gao H, Kelsey D, Quintana H, et al. Cardiovascular effects of atomoxetine in children, adolescents and adults. Drug Saf 2003;26:729-40.
13. Lee TSW, Lee TD, Lombroso PJ, King RA. Atomoxetine and tics in ADHD (letter). J Am Acad Child Adolesc Psychiatry 2004;43:1068-9.
14. Bond GR, Garro AC, Gilbert D. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs (abstract). J Toxicol Clin Toxicol 2004;42:731-2.